Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00432263|
Recruitment Status : Withdrawn
First Posted : February 7, 2007
Last Update Posted : April 22, 2015
|Condition or disease||Intervention/treatment||Phase|
|Brain Injuries||Drug: Genotropin (PN-180,307) Somatropin||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Placebo-Controlled Trial On The Efficacy Of Growth Hormone Replacement Therapy In Patients With Growth Hormone Deficiency After Traumatic Brain Injury|
|Study Start Date :||April 2007|
- The primary endpoint is the change from baseline in the CogState™ composite score at Week 36.
- Change CogState™ at Week 12, 24, 60 and 72. Change in lean body mass and fat mass at Week 36 and 72. Change in the Extended Glasgow Outcome Scale at week 36 and 72. Change in quality of life at week 24, 36, 60 and 72. Summary of change in cardiovascular
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00432263
|Study Director:||Pfizer CT.gov Call Center||Pfizer|